The effect of cannabidiol (300 mg) on fear conditioning.

No registrations found.

Ethical review	Not applicable
Status	Pending
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON28474

Source
NTR

Health condition

Anxiety, fear conditioning
Angst, angstconditionering

Sponsors and support

Primary sponsor: Utrecht University
Source(s) of monetary or material Support: NWO/ZonMw

Intervention

Outcome measures

Primary outcome

Both subjective and objective parameters pertaining to fear conditioning and fear extinction will be assessed, the main physiological measure is the fear potentiated startle reflex.

Secondary outcome

n.a.

Study description

Study design

fear acquisition, fear expression, fear extinction, fear retention, reinstatement

Intervention

Capsule with 300 mg cannabidiol of placebo

Contacts

Public
Febe Flier, van der
Utrecht
The Netherlands
Scientific
Febe Flier, van der
Utrecht
The Netherlands

Eligibility criteria

Inclusion criteria

- Male or female volunteers between 18 and 30 years.

- Judged to be in good physical and mental health on the basis of the medical history according to self-report.

- Have a normal binocular acuity, corrected or uncorrected.

- Female participants must declare they are on reliable birth control.

Exclusion criteria

- History of any disease, e.g. neurological disorders, psychiatric disorders, which in the opinion of the investigator may confound the results of the study.

- Present any other conditions in that in the investigators', the subjects' personal or the study physicians' opinion may confound the results of the study.

- History of psychotic disorder/psychosis and/or having a first/second degree family member with (a history of) psychotic disorder/psychosis.

- Current diagnosis of an Axis I or Axis II psychiatric disorder, or suffering from an Axis I or Axis II psychiatric disorder within 4 weeks prior to the study.

- Current cardiac disease and/or history of cardiac disease.

- Known hypersensitivity to CBD.

- History of cannabinoids exopsure with adverse reactions.

- History of severe allergy or general drug hypersensitivity.

- History of abuse or current regular use of cannabis more than once a week.

- Usage of psychoactive drugs in the four weeks prior to the study.

- Current use of drugs of abuse or indications (urine screening)

- History of epilepsy.

- Pregnancy, i.e., a positive β-HCG urine test.

- Lactating.

- Reduced startle reactivity, defined as no discernable response in at least 3 out of the 12 startle stimuli presented at screening.

Study design

Design

Study type:	Interventional
Intervention model:	Factorial
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	01-01-2018
Enrollment:	56
Type:	Anticipated

Ethics review

Not applicable

Application type:	Not applicable

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL6714
NTR-old	NTR6893
Other	: METC NL63520.041.17

Study results